The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling.
Desai BM; Villanueva J; Nguyen TT; Lioni M; Xiao M; Kong J; Krepler C; Vultur A; Flaherty KT; Nathanson KL; Smalley KS; Herlyn M; Plos One, 2013, vol. 8, issue 3, p e59588, ISSN 19326203. ISBN 19326203.

Full Text Resources Located for this Citation

View article on EBSCOhost(Login required)
View article via CrossRef